Lifevantage (LFVN) Competitors

Lifevantage has lower revenue, but higher earnings than Yatsen. Yatsen is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Yatsen has a beta of -1.71, suggesting that its stock price is 271% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

In the previous week, Lifevantage had 1 more articles in the media than Yatsen. MarketBeat recorded 1 mentions for Lifevantage and 0 mentions for Yatsen. Lifevantage's average media sentiment score of 1.11 beat Yatsen's score of 0.00 indicating that Lifevantage is being referred to more favorably in the news media.

Lifevantage has a net margin of 2.78% compared to Yatsen's net margin of -4.63%. Lifevantage's return on equity of 21.56% beat Yatsen's return on equity.

Lifevantage has a consensus target price of $5.50, suggesting a potential downside of 8.18%. Given Lifevantage's stronger consensus rating and higher probable upside, analysts plainly believe Lifevantage is more favorable than Yatsen.

35.3% of Lifevantage shares are owned by institutional investors. 29.0% of Yatsen shares are owned by company insiders. Comparatively, 13.6% of Lifevantage shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lifevantage has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Nu Skin Enterprises has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Lifevantage pays an annual dividend of $0.20 per share and has a dividend yield of 3.3%. Nu Skin Enterprises pays an annual dividend of $0.24 per share and has a dividend yield of 5.0%. Lifevantage pays out 50.0% of its earnings in the form of a dividend. Nu Skin Enterprises pays out -5.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Lifevantage has raised its dividend for 3 consecutive years. Nu Skin Enterprises is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Lifevantage had 1 more articles in the media than Nu Skin Enterprises. MarketBeat recorded 1 mentions for Lifevantage and 0 mentions for Nu Skin Enterprises. Lifevantage's average media sentiment score of 1.11 beat Nu Skin Enterprises' score of 0.38 indicating that Lifevantage is being referred to more favorably in the media.

Nu Skin Enterprises has higher revenue and earnings than Lifevantage. Nu Skin Enterprises is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Lifevantage has a net margin of 2.78% compared to Nu Skin Enterprises' net margin of -15.73%. Lifevantage's return on equity of 21.56% beat Nu Skin Enterprises' return on equity.

Lifevantage currently has a consensus target price of $5.50, suggesting a potential downside of 8.18%. Given Lifevantage's stronger consensus rating and higher possible upside, research analysts plainly believe Lifevantage is more favorable than Nu Skin Enterprises.

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 82.8% of Nu Skin Enterprises shares are owned by institutional investors. 13.6% of Lifevantage shares are owned by insiders. Comparatively, 2.8% of Nu Skin Enterprises shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

79.4% of Nature's Sunshine Products shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 3.1% of Nature's Sunshine Products shares are held by company insiders. Comparatively, 13.6% of Lifevantage shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Nature's Sunshine Products has a net margin of 3.68% compared to Lifevantage's net margin of 2.78%. Lifevantage's return on equity of 21.56% beat Nature's Sunshine Products' return on equity.

Nature's Sunshine Products has higher revenue and earnings than Lifevantage. Nature's Sunshine Products is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Nature's Sunshine Products has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

In the previous week, Nature's Sunshine Products had 1 more articles in the media than Lifevantage. MarketBeat recorded 2 mentions for Nature's Sunshine Products and 1 mentions for Lifevantage. Nature's Sunshine Products' average media sentiment score of 1.43 beat Lifevantage's score of 1.11 indicating that Nature's Sunshine Products is being referred to more favorably in the media.

Nature's Sunshine Products currently has a consensus price target of $30.50, suggesting a potential upside of 142.64%. Lifevantage has a consensus price target of $5.50, suggesting a potential downside of 8.18%. Given Nature's Sunshine Products' stronger consensus rating and higher possible upside, equities analysts clearly believe Nature's Sunshine Products is more favorable than Lifevantage.

Lifevantage has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market.

Niagen Bioscience has lower revenue, but higher earnings than Lifevantage. Niagen Bioscience is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

In the previous week, Niagen Bioscience had 3 more articles in the media than Lifevantage. MarketBeat recorded 4 mentions for Niagen Bioscience and 1 mentions for Lifevantage. Lifevantage's average media sentiment score of 1.11 beat Niagen Bioscience's score of 0.18 indicating that Lifevantage is being referred to more favorably in the media.

Lifevantage presently has a consensus price target of $5.50, indicating a potential downside of 8.18%. Niagen Bioscience has a consensus price target of $10.33, indicating a potential upside of 288.47%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than Lifevantage.

35.3% of Lifevantage shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 13.6% of Lifevantage shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Niagen Bioscience has a net margin of 12.39% compared to Lifevantage's net margin of 2.78%. Lifevantage's return on equity of 21.56% beat Niagen Bioscience's return on equity.